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Abstract-The characteristics of aminoglycoside uptake in the inner ear were investigated in the 
isolated crista ampullaris. The organ was incubated with radiolabeled gentamicin, and the stable, non- 
exchangeable radioactivity was considered the intracellular pool of the drug. Gentamicin was transported 
against a concentration gradient, and the resulting tissue to medium ratios ranged from 1.4 to 18.6. 
Transport was inhibited by reduction in temperature or by the addition of metabolic blockers, indicative 
of an energy-dependent component. The uptake system showed at least two sites, the first a high-affinity 
site with a dissociation constant Kv = 39 nM and a capacity of A = 0.2 pmole/crista; the second had a 
Kv = 16 ph4 and a capacity of 12 = 11 pmoles/crista. Aminoglycosides competed with uptake of genta- 
micin in the order netilmicin 2 neomycin > tobramycin, and polyamines competed in the order spermine 
> spermidine > putrescine; glucosamine and the basic amino acids lysine and asparagine were ineffective, 
excluding the participation of glucose and basic amino acid transport systems in gentamicin uptake. 
These results along with direct comparisons with some characteristics of putrescine uptake suggest that 
aminoglycoside and polyamine transport have common features in the crista ampullaris. 
The existence of an active cellular uptake mechanism 
for aminoglycoside antibiotics has been well estab- 
lished in bacteria and in the kidney. Bacterial uptake 
of aminoglycosides proceeds in two energy-depen- 
dent phases, is susceptible to competition by amino 
acids and divalent cations, and is inhibited by block- 
ers of electron transport and uncouplers of the pro- 
tonmotive force [ 11. Renal drug uptake has also been 
described in some detail and is known to be energy 
dependent [2-51. 
Evidence has been presented only recently that 
the inner ear may also possess an active transport 
system for aminoglycosides. The pharmacokinetics 
of gentamicin in the inner ear [6] indicated that the 
drug occupies two distinctly different binding sites in 
the course of its action. Electrophysiological studies 
of its cochlear toxicity [7] suggested the presence of 
an extracellular and an intracellular compartment. 
In addition, it was shown that an energy-dependent 
step is required for the expression of gentamicin 
ototoxicity [8]. More recently, Schacht and Van De 
Water directly demonstrated the uptake and accumu- 
lation of gentamicin in the developing inner ear in 
culture [9]. 
While this evidence strongly supports an active 
transport of aminoglycosides in the inner ear, its 
mechanisms remain to be elucidated. The aim of this 
study was to examine and characterize the amino- 
glycoside uptake system in the inner ear. The crista 
ampullaris of the guinea pig was chosen since this 
vestibular structure is susceptible to damage by 
aminoglycosides and is easily and consistently dis- 
sected. In addition, an earlier study of gentamicin 
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binding had shown the usefulness of this preparation 
for reproducible in vitro incubations [lo]. 
MATERIALS AND METHODS 
Dissection. Cristae ampullares were dissected from 
pigmented guinea pigs (180-240 g; Murphy Breeding 
Laboratories, Plainsfield, IN). After decapitation 
the temporal bones were separated into the cochlear 
and vestibular parts and placed in Hanks’ balanced 
salt solution with an osmolarity of 300 mOsM (Gibco 
Co., Grand Island, NY) at room temperature. The 
cristae were removed intact and the ampullae were 
opened with microscissors to permit tree diffusion of 
the medium. 
Uptake studies. Isolated cristae were incubated 
individually in polypropylene tubes (because of the 
affinity of aminoglycosides and polyamines for glass 
surfaces) at 37” in a final volume of 0.20 ml of Hanks’ 
solution (136.9 mM NaCl, 4.16 mM NaHC03, 
0.33 mM Na2HP04, 5.37mM KCl, 0.44mM 
KH2P04, 0.49 mM MgC12, 1.26 mM CaC12, 5.5 mM 
glucose; pH, 7.4). The additional assay components 
and some details of the incubation varied with the 
individual experiments as described below. The fol- 
lowing rea 
0.5 ,uCi Q 
ents were added: for gentamicin uptake, 
l2 I-labeled gentamicin (19.9 Ci/mmole; 
American Bioclinical, Portland, OR) and unlabeled 
gentamicin to a final concentration of 1 PM, except 
as noted in the gentamicin dose-response study; for 
putrescine uptake, 0.1 @i [l ,4J4C]putrescine 
dihydrochloride (109 mCi/mmole; Amersham 
Corp., Arlington Heights, IL); (final concentration, 
4.6pM); for y-aminobutyric acid (GABA) uptake, 
0.008 @i y-[2,3-3H(N)]-aminobutyric acid (98.5 Ci/ 
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mmole; New England Nuclear, Boston, MA) and 
unlabeled GABA to a final concentration of 1 ,uM; 
for mannitol uptake, 0.135 @i D-[ l-3H(N)]-man- 
nitol(17 Ci/mmole; New England Nuclear); and for 
butanol uptake, 0.17 &i [14C]butanol (gift from Dr. 
N. Weiner, The University of Michigan). 
The reactions were started by the addition of a 
crista to the incubation mixture except for ,experi- 
ments in which inhibitors or competitors were tested. 
In these cases, each crista was preincubated for 5 min 
in the presence of the antagonist, and the incubation 
was started by the addition of the radiolabeled 
compound. 
At the end of the incubation period, the radio- 
active medium was replaced by 1 ml of medium 
containing 1 mM unlabeled compound. Five minutes 
thereafter the crista was separated on a Millipore 
RA filter (Millipore Corp., Bedford, MA) and rinsed 
with 10 ml of Ringer’s solution. The filter area con- 
taining the crista was cut out, dissolved in 50 @ of 
1 N NaOH (30min at SO’) and neutralized with 
150 ml acetic acid (glacial acetic acid in HZ0 , 1: 40). 
Radioactivity was determined by liquid scintillation 
counting. A filter area of the same size adjacent to 
the crista was used as a correction for radioactivity 
bound to the filter. 
The incubations with labeled butanol were ter- 
minated by removal of the crista from the medium 
with forceps. The tissue was briefly (approx. 5 set) 
rinsed in Ringer’s solution, dissolved in 50 ~1 of 1 N 
NaOH, neutralized with acetic acid, and counted. 
Materials. Tobramycin, gentamicin and netilmicin 
were from the Schering Co. (Bloomfield, NJ), and 
neomycin from Pharma-Tek (Huntington, NY). All 
other chemicals were obtained from the Sigma 
Chemical Co. (St. Louis, MO). 
Data analysis. The bound (CB) and free (CF) 
concentrations of gentamicin were fitted to a protein 
binding model which incorporates a single Langmuir 
term plus a constant: 
CB=ni + 
nr*CF 
KD, + CF 
nl represents the binding capacity for the high-affin- 
ity, low-capacity binding site; n2 and Ko2 represent 
the binding capacity and dissociation constant, 
respectively, for the low-affinity, high-capacity bind- 
ing site. Equation 1 is derived from a binding model 





KD1 + CF KLZ + CF (2) 
q, n2, and KD2 are the same as described previously; 
KD1 is the dissociation constant for the high-affinity, 
low-capacity binding site. When the free con- 
centrations of gentamicin are much larger than the 
high-affinity dissociation constant (CF >> KD1), 
Equation 2 simplifies to Equation 1. 
The binding parameters in Equations 1 and 2 were 
estimated by nonlinear regression using the MK 
MODEL program of the PROPHET computer sys- 
tem [ll, 121 and a weighting function 1/Y2. Other 
models were tested (i.e. single Langmuir, single 
Langmuir plus linear term), but these did not fit the 
data well, as judged by their log-likelihood estimates 
[12,13]. The quality of the fits was further deter- 
mined by evaluatin 
3 
standard error of the 
parameters, multiple- of the regression line, and 
by visual inspection of the residuals. 
Other statistical procedures were Student’s t-test 
and ANOVA, as mentioned in the legends of the 
respective data. 
RESULTS 
Preliminary experiments were designed to discri- 
minate between intracellular drug uptake and drug 
either externally bound to the crista membrane or 
trapped within extracellular spaces. At the end of the 
incubation the medium was replaced with medium 
containing unlabeled drug at a lOOO-fold higher con- 
centration to displace all but the intracellular genta- 
micin. This post-incubation “wash” (Fig. 1) caused 
a rapid loss of about 40% of the radioactivity from 
the crista followed by a period of a stable radioactive 
content for at least 15 min. This stable radioactivity 
was defined as the intracellular drug content. All 
subsequent assays included a 5-min postincubation 
prior to filtration. 
Possible trapping in extracellular spaces was 
additionally tested with radiolabeled mannitol, a 
marker which is not transported into cells. Under 
analogous conditions to the gentamicin assay (i.e. 
inclusion of a post-incubation “wash”), radioactivity 
in the crista did not exceed background counts 
significantly. 
Incubations with an excess of native gentamicin 
(10 mM) displaced all 1251-labeled gentamicin and 
reduced the bound radioactivity to background, indi- 
cating that the radioactive gentamicin used in these 
experiments had the same binding characteristics as 
the native drug. 
Gentamicin uptake was essentially linear at early 
times (Fig. 2). Uptake at 30min was consistently 
high, while an apparent loss of drug at 60min was 
seen in two experiments. Therefore, a 30-min time 
point was chosen for subsequent incubations. The 
uptake was temperature dependent (Fig. 3) and 
reduced by 81% at O”, indicating an active transport 
system. In contrast, uptake of butanol, which enters 
cells by diffusion only, was independent of tem- 
perature (2650 + 1300 cpm at 37” versus 2500 & 
1100 cpm at 0’). 
The dose-dependency of the uptake (Fig. 4) was 
analyzed for the affinity and capacity of the transport 
system. Table 1 lists the parameter estimates (& SE) 
by the two binding models. Both analyses clearly 
demonstrate that two classes of binding sites are 
needed to describe the uptake of gentamicin. Each 
of the parameters derived by Equation 1 was well 
characterized, as evidenced by the small coefficients 
of variation (CV < 16%). The correlation between 
the observed data and the computer-generated 
regression curve was excellent. A good fit was also 
achieved with the binding model described by 
Equation 2 (Fig. 4, insert). It should be noted that 
the estimates by Equations 1 and 2 are within 10% 
of each other for n2 and Ko2, and within 25% of each 
other for ni. Less confidence can be placed on the 
numerical value of KDl due to the large variability 
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Fig. 1. Effect of post-incubation on [12SI]gentamicin content of cristae. Cristae ampullares were incubated 
with 1 @I i2SI-labeled gent~i~in for 30 min as described in Materials and Methods and were then 
transferred to a post-incubation medium containing 1 mM unlabeled gentamicin. Points are from 
individual cristae except at 0 time (N = 2) and 15 min (N = 3; means f SD). 
surrounding it (CV > 200%). The inability of the be obtained. This restraint was placed on the experi- 
regression program to characterize this constant ments by the specific radioactivity of the 
equally well as the others may be based on the fact [1251]gentamicin. 
that experimental data points below KD1 could not The dose-dependency study also showed that 
IO 20 30 ” 60 
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Fig. 2. Time-course of gentamicin uptake. Cristae amp&ares were incubated with 1@4 gentamicin as 
described in Materials and Methods. Numbers are means + SD from three experiments. 
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Fig. 3. Effect of temperature on gentamicin uptake. Cristae 
ampullares were incubated for 30 min with 1 @I gentamicin 
at the temperatures indicated. Before the start of the incu- 
bation, cristae had been equilibrated to the respective 
temperatures for 5 min. Numbers are means f SD of 
triplicate determinations. 
gentamicin concentrations in the tissue (average wet 
weight of a crista, 40 pg) always exceeded those in 
the medium. The tissue to medium ratio was highest 
(18.6) at the Iowest drug concentration in the 
medium and declined to 1.4 at 100 nM gentamicin in 
the medium. 
16 
Gentamicin uptake was significantly inhibited by 
other aminoglycosides and polyamines (Table 2). 
Neomycin, tobramycin and netilmicin inhibited 
gentamicin uptake in a dose-dependent manner in 
the order netilmicin 2 neomycin > tobr~ycin, 
with 80-90% inhibition at a 100 PM concentration of 
each drug. Spermine was the most efficient com- 
petitor among the polyamines followed by sper- 
midine and putrescine. Conversely, gentamicin 
inhibited putrescine uptake (Table 3). Neither 
glucosamine nor the basic amino acids asparagine 
and lysine affected genta~cin uptake, whereas 
putrescine uptake was inhibited significantly by 
lysine (60% at 1 mM) and asparagine (44% at 1 mM). 
In addition to the compounds mentioned, the cat- 
echolamines epinephrine and norepinephrine were 
tested and found to have no effect on gentamicin 
uptake at 10 @I. 
The addition of metabolic blockers to the incu- 
bations caused a partial inhibition of gentamicin 
transport (Table 4). Ouabain reduced uptake by 
24%) whereas iodoacetate and 2,4-dinitrophenol 
(DNP) were less effective. A potential transport 
inhibitor, the sulfhydryl group blocker p-chlo- 
romercu~be~oic sulfonate ( pCMBS), and colchi- 
tine, which blocks pinocytosis, did not affect genta- 
micin uptake significantly. The effects of these agents 
on putrescine transport were not significantly dif- 
ferent from their effects on gentamicin transport. In 
contrast, a brief comparison with the high-affinity 
uptake of GABA showed significant differences in 
the response of this system to low temperature 
(completely inhibited by ice) and metabolic blockers 
(inhibited 65% by DNP, and 77% by ouabain). 
6 5 4 
GENTAMICIN &log Mt 
Fig. 4. Dose-dependency of gentamicin uptake. Cristae ampullares were incubated for 30 min with the 
indicated concentrations of gentamicin at 37” (w) or 0” (A-A). Numbers are means -C SD of 
triplicate determinations, Insert: Computer-fitted curve (by Equation 2; see Materials and Methods) to 
the experimental data of the temperature-sensitive uptake, i.e. values of the incubation at 0” subtracted 
from the values of uptake at 37’. 
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Table 1. Parameters of gentamicin uptake 
Method of 
calculation hl n2 KD, KD, ?J* log Lt 
( pmoles/crista) (nM) 
Equation 1 0.18 ” 0.03$ 11.0 2 1.1 15,011 ? 2,382 0.9998 -5.27 
Equation 2 0.24 ” 0.12 11.2 * 1.3 39.2 * 79.4 16,313 f 3,979 0.9998 -4.87 
* Multiple -9 of the regression line. 
t Log-likelihood estimate [ 12,131. 
$ Numbers are parameter estimates ? SE of the regression parameters. 
DISCUSSION 
In an intact organ such as the crista ampullaris, a 
drug may occupy several distinct locations: extra- 
cellular spaces, extracellular binding sites and intra- 
cellular compartments. Before mechanisms of 
uptake can be characterized the extracellular con- 
tributions need to be assessed and, if possible, elim- 
inated. This seems particularly important in a study 
of gentamicin, where extracellular drug binding may 
be a quantitatively major factor due to the high 
affinity of aminoglycosides for negatively charged 
surface components. Our experimental design de- 
fines intracellular gentamicin as being sequestered in 
a stable, not easily exchangeable pool. This pool is 
experimentally isolated by a post-incubation with 
excess unlabeled drug which causes a rapid dis- 
placement of about 50% of the initially present radio- 
activity, This rapid displacement is indicative of 
superficial binding sites and the stable radioactivity 
Table 2. Effect of competitors on gentamicin uptake 
Uptake (% of control) 
Competitor Concentration of competitor 
1pM 10pM 100/&l 1mM 
Netilmicin* 53 + 35 362 8 162 4 
Neomycin 71 r 12 52 ” 14 lo? 1 
Tobramycin 922 13 71* 9 182 8 
Putrescinet 72 f 21 72211 75? 5 
Spermidine 69 * 21 59rll 24214 
Spermine 892 9 22* 4 
Asparagine$ 110 z? 40 90 2 23 143 f 15 
Lysine 124 + 8 73” 2 193 2 52 
Glucosamine 90 f 17 95? 27 1202 1 
Uptake was analyzed at 1 ,&I gentamicin as described in 
Materials and Methods. Numbers are means + SD of at 
least triplicate determinations. Control value for genta- 
micin uptake was 1.05 ? 0.31 pmoles/crista (N = 75). 
* Treatment differs from control, P < 0.01 for each 
aminoglycoside; differences between drugs: netilmicin vs 
tobramycin, P < 0.01; netilmicin vs neomycin, P = 0.27; 
neomycin vs tobramycin, P = 0.025 (two-way ANOVA). 
t Treatment differs from control, P < 0.01 for each poly- 
amine; differences between polyamines (at lOO@i and 
1 mM): putrescine vs spermidine, P < 0.01, putrescine vs 
spermine, P < 0.01; spermidine vs spermine, P < 0.069 
(ANOVA). 
$ Treatment with asparagine, lysine, glucosamine, not 
different from control. 
signifies a deeper compartment. The absence of 
extracellular trapping in the crista was also confirmed 
in incubations with mannitol, a marker of extra- 
cellular spaces. After analogous procedures, no 
radioactivity was incorporated into the cristae. 
In contrast to the retention of radiolabeled genta- 
micin in the presence of an excess of unlabeled drug 
after the incubation, all radioactivity was eliminated 
when such an excess of unlabeled gentamicin was 
added to the initial incubation. This displacement 
demonstrated that non-specific binding of 
[rZ51]gentamicin did not occur as all binding sites were 
accessible to the native drug. This documentation 
of 1251-labeled gentamicin as a valid substitute for 
gentamicin is in agreement with Humes et al. [14] 
who studied the renal binding of this compound. 
Several lines of evidence point to an energy-depen- 
dent process underlying or at least contributing to 
the uptake of gentamicin in the crista. First, the 
uptake occurred against a concentration gradient 
yielding a tissue to medium ratio of 1.4 to 18.6, 
depending on the drug concentration in the medium. 
This was remarkably similar to observations in the 
developing inner ear where tissue levels of genta- 
micin exceed those in the medium up to 17-fold 
[9]. Likewise, kidney slices have been reported to 
transport gentamicin actively to a 2- to 5-fold excess 
in the tissue. Second, the uptake was temperature- 
dependent; 80% could be eliminated by cooling the 
crista to 0 or 10”. The remaining 20% may represent 
a fraction of the drug entering by diffusion. Diffusion 
is unaffected by temperature as seen in the temp- 
erature-independence of the tissue levels of butanol, 
which enters cells exclusively by this process. 
Table 3. Effects of competitors on putrescine uptake 
Uptake (% of control) 
Concentration of competitor 
Competitor 100 PM 1mM 
Gentamicin 70 f 24 56 -c 15* 
Asparagine 80 2 22 56 +z 22t 
Lysine 512 6 40 2 14t 
Uptake was analyzed at 1 @ putrescine as described in 
Materials and methods. Numbers are means 2 SD of at 
least triplicate determinations. Control value for putrescine 
uptake was 4.01 * 1.7 pmoles/crista (N = 30). 
* Treatment differs from control, P = 0.02. 
t Treatment differs from control, P < 0.01. 
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Table 4. Effects of inhibitors on uptake 
Uptake as (% of control) 
Inhibitor Gentamicin Putrescine GABA 
Ice 19 + 12* 5 * 3‘ 0 * 0*,t 
Ouabain 76 2 19* 56 + 16* 23 f 16*,$ 
DNP 87 + 10 73 I?: 29 35 + ll*,$ 
Iodoacetate 88 2 14 ND ND 
pCMBS 138 + 30 74 -+ 37 
Colchicine 82 + 24 73 rfr 27 Z 
Cristae were incubated with the inhibitors and radi- 
olabeled gentamicin, putrescine or GABA as described 
in Materials and Methods. Inhibitor concentrations were 
DNP, 1 mM; ouabain, 1 mM; iodoacetate, 10 mM; pCMBS 
(para-chloromercuribenzoic sulfonatc), 50 &YI; and col- 
chicine, 2 PM. “Ice” indicates a 30-min incubation on ice. 
Numbers are means c SD of three to nine experiments per 
inhibitor, each in triplicate. ND = not determined, Control 
uptake values: gentamicin, 1.05 -+ 0.31 pmofes/crista (N = 
75); putriscine, 4.01 + 1.7 pmoies/crista (N = 30); and 
GABA, 0.196 + 0.08 pmoles/crista (N = 10). 
* Differs from control, P < 0.01 (paired r-test). 
t Differs from effect on gentamicin uptake, P = 0.028. 
$ Differs from effect on gentamicin uptake, P < 0.01. 
Gentamicin uptake was also partially susceptibIe 
to metabolic inhibitors. In the absence of an inde- 
pendent measure of ATP levels in the tissue, the 
significance of this partial block remains uncertain. 
It is possible that these agents require longer incu- 
bation times to exert their actions. For example, 
iodoacetate effectively blocks renal gentamicin 
uptake after 60 min but is ineffective at short incu- 
bation times [4]. 
The active transport system, defined as the dif- 
ference between uptake at 37” and O”, had at least 
two components. The first was a Hugh-affinity system 
with a remarkably low Kr, = 39 nM and a capacity 
of 0.2 pmole/crista. The second site was cleariy evi- 
dent in the analysis although no saturation of uptake 
was achieved under the experimental conditions. 
Both the affinity and capacity of the second site were 
several orders of magnitude different from those of 
the first site: K. = 16 PM, n = 11 pmoles/crista. 
Gentamicin appears to enter the crista, at least 
in part, by the polyamine transport system. The 
polyamines inhibited gentamicin uptake in the order 
of their increasing positive charge, spermine > sper- 
midine > putrescine, an observation similarly made 
in the kidney [15]. Gentamicin, in turn, competed 
with putrescine uptake. The direct comparison of 
gentamicin and putrescine uptake did not show any 
significant difference in the effect of potential inhibi- 
tors on these two systems. In contrast, the uptake 
for the amino acid GABA reacted significantly dif- 
ferently to such treatment. The responses of genta- 
micin and putresoine uptakes to basic amino acids 
and giucosamine, however, were not parallel. This 
discrepancy could be resolved by the assumption 
that putrescine, bBt not gentamicin, could also be 
transported by the basic amino acid transport system 
in the crista ampullaris. Then part of the total poly 
amine but not gentamicin uptake would be sus- 
ceptible to inhibition by amina acids. 
Glucosamine (Zamino-D-glucose), an inhibitor of 
glucose uptake, was included in this study because 
of suggestions that aminoglycosides may exert their 
toxic actions through interference with glucose trans- 
port [Hi]. Gentamicin uptake was unaffected by 
glucosamine, confirming our previous findings that 
inhibition of glucose uptake and utilization is not a 
primary mechanism of aminoglycoside toxicity 
[17,18]. 
A number of parallels are evident between the 
renal uptake system and that in the crista. As pointed 
out above, drug accumulatiun, temperature depen- 
dence, and sensitivity to metabolic blockers are simi- 
lar. The parameters of uptake by the second site in 
the crista are well in the range of those reported for 
uptake in renal brush border membranes [19,20]. 
Furthermore, gentamicin uptake in both tissues is 
competitive with other ami~uglycosides and poly- 
amines, but not with basic amino acids [4,5, IS, 211. 
These paralfeIs suggest that a similar uptake system 
is an important element in the toxicity of amino- 
glycosides to both the kidney and the inner ear. 
In assessing the contribution of the active transport 
to the toxicity of the aminoglycosides, two aspects 
should be noted. The first is the very high affinity 
of the uptake system (K, = 39 nM) which should 
pruvide for an efficient tissue entry d these drugs 
even at low serum concentrations. The second point 
is that the order of affinity for the uptake system, 
netilmicin = gentamicin 3 neomycin > tobramycin 
is not the order of the vestibule- or cochleotoxicity 
of these drugs, Thus, while the active uptake may 
aid in achieving toxic drug concentrations in the 
affected tissues and thus represent an integral part 
of the ototoxic mechanism, it is not the step that 
determines the extent of drug toxicity in that tissue, 
Those controls may lie-as we have demonstrated 
before-in specific drug interactions with other intra- 
cellular components such as phosphatidylinositol45 
bisphosphate [22]. 
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